Investing.com -- Aquestive Therapeutics (NASDAQ:AQST) stock rose 18% Monday despite the company announcing it received a complete response letter (CRL) from the U.S. Food and Drug Administration for ...

Please provide your email address to receive an email when new articles are posted on . The FDA was not concerned about the drug’s pharmacokinetics. Concerns included packaging, patient use and ...

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Tracker, the AI-powered ATS and CRM platform built for staffing and recruiting agencies, today announced the general availability of its new Open API following ...

We all know sleep is important, but with endless advice promising better rest, it can be hard to know where to start. Whether you struggle to fall asleep or simply want to improve your sleep quality, ...

The challenge fee is non-refundable Objections will not be accepted after February 6, 2026 (11:50 pm) Challenges can be submitted only through online mode No individual candidate will be informed ...

WARREN, N.J. - Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced Monday it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its Anaphylm sublingual film, a ...

The FDA issued complete response letters (CRLs) to two companies in recent days, resulting in vastly different reactions from the market. The U.S. regulator rejected Pharming’s bid to gain an ...

ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...

Update: Self-administered Saphnelo remains under FDA review in the U.S. The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from AstraZeneca ...

Mallory Terry does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...